Chirally-enriched double-stranded RNA agents
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsMuthiah Manoharan, Nate Taneja, Hartmut Ingo Jahns, Shigeo Matsuda, Klaus Charisse, Guo He, Jayaprakash K. Nair, Christopher Brown, Mark K. Schlegel, Vasant Jadhav, Martin Maier
Life of this patent
Estimating the term…
Abstract
The present invention relates to a chirally-modified dsRNA agent capable of inhibiting the expression of a target gene. The sense and antisense strands of chirally-modified dsRNA agent independently or in combination comprises one or more site specific-site specific/position specific, chirally-modified internucleotide linkages.
Claims24
A chirally-modified double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene, said chirally-modified dsRNA agent comprising a sense strand and an antisense strand, each strand having 14 to 40 nucleotides,
- wherein:
- the sense strand comprises one or more terminal, chirally-modified internucleotide linkages at the 5′ end;
- the antisense strand comprises one or more terminal, chirally-modified internucleotide linkages at the 5′ end and one or more terminal, chirally-modified internucleotide linkages at the 3′ end;
- each terminal, chirally-modified internucleotide linkage is a phosphorothioate linkage;
- a terminal, chiral modification occurs at the first internucleotide linkage at the 3′ end of the antisense strand, and the linkage phosphorus atom is in Sp configuration;
- and
- a terminal, chiral modification occurs at the first internucleotide linkage at the 5′ end of the antisense strand, and the linkage phosphorus atom is in Rp configuration.
Dependencies are inferred from the claim text.